Treximet

Treatment for Migraine

Update: Treximet Now FDA Approved - April 15, 2008

POZEN Submits New Drug Application for Trexima (Sumatriptan Succinate and Naproxen Sodium) for the Acute Treatment of Migraine

CHAPEL HILL, N.C., August 8, 2005 - POZEN Inc. (NASDAQ: POZN) announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the marketing approval of Trexima, the proposed brand name for the combination of sumatriptan succinate, formulated with RT Technology (TM), and naproxen sodium, in a single tablet for the acute treatment of migraine.

Dr. Marshall Reese, executive vice president, product development stated, "We are pleased to submit the Trexima NDA ahead of schedule and within four months from the database lock on the last pivotal clinical study for the NDA. This has been a well-executed development program with good collaborative efforts put forth by team members from both GlaxoSmithKline (GSK) and POZEN."

About Migraine

Migraine affects more than 28 million people in the Unites States alone, of which roughly three out of four migraine sufferers are women. According to the International Headache Society's diagnostic criteria, migraine is characterized by recurrent headaches lasting 4 to 72 hours (untreated) and with symptoms including moderate to severe headache pain, throbbing head pain, head pain located on one side of the head, head pain aggravated by routine activity, nausea, vomiting, and sensitivity to light and sound. Migraine can be disabling and sufferers may miss days of work, lose time with family and friends, and be unable to pursue basic daily activities.

Source: POZEN Inc.

Posted: August 2005

Related Articles

Treximet (sumatriptan succinate and naproxen sodium) FDA Approval History

View comments

Hide
(web4)